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Abstract: Two new 20-membered macrolides, levantilide A and B, were isolated from the 
Micromonospora strain M71-A77. Strain M71-A77 was recovered from an Eastern 
Mediterranean deep-sea sediment sample and revealed to produce the levantilides under in 
situ salinity of 38.6‰. The chemical structures of the levantilides were elucidated on the 
basis of different one- and two- dimensional NMR experiments. Levantilide A exhibits a 
moderate antiproliferative activity against several tumor cell lines. 
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1. Introduction  
The deep sea is an extreme environment which is still marginally investigated and harbors a great 
variety of bacteria that have, so far, not been cultivated. Bacteria which live in the deep sea need to 
adapt to the specific environmental characteristics such as high hydrostatic pressure, low temperature 
and only occasional nutrient supply. These constraints quite likely determine the phylogenetic 
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diversity of the deep-sea bacterial communities and also affect the secondary metabolite production of 
these bacteria. Therefore, deep-sea bacteria are considered as a promising source for the discovery of 
new natural products. Marine members of Actinobacteria are highly potent producers of interesting 
compounds [1–5] as was already shown for their terrestrial counterparts [6]. Only recently, two strains 
of Streptomyces sp. from the Atlantic ocean deep-sea sediment were shown to produce the two new 
natural products caboxamycin and albidopyrone [7,8]. 
With special focus on the discovery of new natural products, we selectively isolated Actinobacteria 
from the deep-sea sediment of the Eastern Mediterranean Sea (the so-called Levantine Sea). This 
environment is characterized by a relatively high bottom temperature of 13–14 °C, salinity values of 
approximately 38–39‰, high hydrostatic pressure (440 bar at the sampling site) and an extreme 
depletion of nutrients [9]. Among the isolated bacteria, strain M71-A77 produced two new macrolides 
named levantilides A (1) and B (2), which will be described in this paper. 
2. Results and Discussion 
Strain M71-A77 was isolated from the Eastern Mediterranean deep-sea sediment (4400 m) and 
revealed 99.3% 16S rRNA gene sequence similarity to Micromonospora auratinigra DSM 44815
T
 
(AB159779). Analyses of the culture extract of this strain (incubated in liquid soja-peptone medium) 
by HPLC-DAD-MS led to the detection of two unknown 20-membered macrolides, levantilide A (1) 
and B (2), with detected masses of m/z 508 and m/z 506, respectively. Subsequent cultivation of the 
strain in larger scale (10 L) led to the isolation of the levantilides as colorless solids.  
 
 
 
 
 
 
 
  
Levantilide A (1) R = OH 
Levantilide B (2) R = O 
Levantilide A (1) had a measured molecular mass of m/z 531.3676 [M + Na]
+ 
(calculated for 
C30H52NaO6 531.3656), which yielded the molecular formula C30H52O6 and implied five degrees of 
unsaturation. The structure elucidation of the compound was mainly based on one- and two- 
dimensional NMR spectra of 1. The respective 
13
C NMR spectrum displayed 30 distinct signals  
(Table 1) which were consistent with the deduced molecular formula. The carbon resonances gave 
evidence of one carbonyl carbon (C 166.1 ppm), one olefinic quaternary carbon (C 132.8 ppm), five 
olefinic methine carbons (C 120.4 ppm to 143.8 ppm), five methine carbons adjacent to oxygen atoms 
(C 67.2 ppm to 77.4 ppm), four further methine carbons (C 29.4 ppm to 41.0 ppm), eight methylene 
groups (C 22.0 ppm to 40.9 ppm) and six methyl groups (C 10.1 ppm to 21.5 ppm). The HSQC 
spectrum allowed all carbon resonances to be unambiguously assigned to the resonances of their 
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directly attached protons. The final planar structure of the molecule was deduced from COSY and 
HMBC spectra (Figure 1). With a shift of 166.1 ppm, the carbonyl carbon C-1 was very likely to 
belong to a conjugated ester function. HMBC correlations from H-3 (H 7.06) and H-2 (H 5.78) 
identified the adjacent methine groups. H-2 to H-5 (H 6.08) were all olefinic protons which coupled to 
each other. H-5 showed HMBC correlations to C-3 (C 143.8) as well as to C-6 (C 39.6), a methylene 
carbon, and C-7 (C 67.2), a hydroxylated methine. H-7 (H 3.98) showed COSY correlations to H-6 as 
well as to the methylene group CH2-8 (C 33.4, H 1.51; 1.16). Next to CH2-8, there followed four 
methine groups, CH-9 to CH-12, each of them substituted with either a hydroxy group, CH-9 (C 67.4, 
H 3.92) and CH-11 (C 75.3; H 2.98), or a methyl group, CH-10 (C 41.0; H 1.68) and CH-12  
(C 32.1 and H 1.24), which could be unequivocally proven by their shifts, COSY and HMBC 
correlations. Not only did the COSY correlations of the methyl groups CH3-29 (C 17.7 and H 0.58) 
and CH3-30 (C 11.1 and H 0.86) connect them to the methine groups CH-12 and CH-10, but their 
HMBC correlations also gave further evidence of the positions of the neighboring carbons and secured 
the sequence from CH-9 to CH-12. Furthermore, a methylene group CH2-13 (C 40.1, H 1.87 and 
1.51) was shown to connect the methine groups CH-9 to CH-12 to the quaternary olefinic carbon C-14 
(C 132.8). Therefore, the last double bond evidently was located between C-14 and C-15 (C 132.7). 
The corresponding proton H-15 (H 4.76) showed long range couplings to C-17 (C 40.9), C-13, C-16  
(C 29.4), C-27 (C 21.5) and C-28 (C 17.0) and coupled to H-16 and H2-13. CH2-17 (H 1.34 and 
1.05) formed the junction between the methyl-bearing methines CH-16 and CH-18 as indicated by 
HMBC correlations from H-17 to C-18 (C 33.4), C-26 (C 17.5) and C-27. The substructure was 
further supported by COSY correlations of the same proton signal (H-17) to the resonances of H-16 
(H 2.59) and H-18 (H 1.75). CH-19 (C 77.4; H 4.71), the methine adjacent to CH-18, closed the 
macrolide ring as proven by its HMBC correlation to C-1 and connected it to the side chain of the 
molecule by correlations to the methylene groups CH2-20 (C 27.9; H 1.52 and 1.47) and CH2-21  
(C 22.0; H 1.30). After the carbonyl group and the three double bonds, one degree of unsaturation 
still had to be accounted for, which was accomplished by the closure of the ring. Analysis of the NMR 
spectra gave evidence of a 3-hydroxy-hexyl-side chain. All double bonds, 2,3, 4,5 and 14,15, were 
determined to be E-configured. For the double bonds 2,3 and 4,5, the configuration was deduced from 
the 
3
J coupling constants of approximately 15 Hz.14,15 is a trisubstituted double bond, therefore the 
NOESY spectrum had to be consulted. As H-15 showed NOESY-correlations to H2-13, but not to  
H3-28, this double bond, too, had to be E-configured. Thus, the planar structure of levantilide A could 
be unambiguously delineated from the spectroscopic data. 
The derivative, levantilide B (2), showed a mass difference of 2 amu in the HPLC-DAD-MS 
measurement, which indicated one additional double bond, which for example can be observed, when 
a hydroxy-group is replaced by a carbonyl function, as it was the case here. Already in the 
1
H NMR 
spectrum it was obvious that all signals belonging to protons of the macrolide ring were identical in 
both molecules (see Table 2). However, significant differences could be observed for the signals of the 
side chain. Analysis of the data showed that the methine group CH-23 was no longer present in 
levantilide B. Instead of it, an additional signal of a carbonyl carbon appeared, its shift of 210.5 ppm 
proving it to be a ketone. As a consequence of the presence of a carbonyl group instead of a methine in 
position 23, the signal of H2-24 was no longer a multiplet, but appeared as a quartet as it only coupled 
with the methyl group CH3-25. Thus, the planar structure of 2 was established as depicted. 
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Table 1. NMR spectroscopic data (500 MHz, DMSO-d6) of levantilide A (1). 
levantilide A (1) 
position  C H, J [Hz] COSY HMBC NOESY 
1 166.1, C        
2 120.4, CH 5.78, d (15.5) 3 1, 3, 4, 5 3, 4 
3 143.8, CH 7.06, dd (11.2, 15.5) 2, 4  1, 2, 4, 5 2, 4, 5 
4 130.6, CH 6.29, dd (11.2, 15.2) 3, 5 2, 3, 6 2, 3, 5, 6b 
5 139.8, CH 6.08, ddd (4.4, 10, 15.2) 4, 6 3, 6, 7 3, 4, 6a, 7 
6a 39.6, CH2 2.57, m 5, 6b, 7 4, 5, 7, 8 5 
6b  2.33, dt (14.4, 9.9) 5, 6a, 7 4, 5, 7, 8 4 
7 67.2, CH 3.98, m 6, 7-OH, 8  8b, 5 
7-OH  4.81, br. d (3.8) 7 7, 8  
8a 33.4, CH2 1.51
a
, m 7, 8b, 9 6, 7, 9 8b 
8b  1.16, ddd (14.6, 5.6, 2.3) 7, 8a, 9 6, 7, 9 7, 8a, 11 
9 67.4, CH 3.92, br. d (11.2) 8, 9-OH, 10 30 12 
9-OH  4.63, br. s 9 8, 9, 10  
10 41.0, CH 1.68, m 9, 11, 30   
11 75.3, CH 2.98 br. ddd (8.9, 6.0, 1.8) 10, 11-OH, 12 9, 10, 12, 13, 29, 30 8b, 29 
11-OH  4.00, d (6.0) 11 10, 11, 12  
12 32.1, CH 1.24, m 11, 13, 29  9 
13a 40.1, CH2 1.87, br. d (12.8) 12, 13b, 15, 29 11, 12, 14, 15, 27, 28, 29 13b 
13b  1.51
a
, m 12, 13a, 15, 29 11, 12, 14, 15, 27, 28, 29 13a, 15 
14 132.8, C     
15 132.7, CH 4.76, d (7.8) 13, 16 12, 13, 16, 17, 27, 28 13b, 17, 29 
16 29.4, CH 2.59, m 15, 17, 27 14, 17, 27 27, 28 
17a 40.9, CH2 1.34, m 16, 17b, 18 15, 16, 18, 19, 26, 27 17b 
17b  1.05, ddd (13.5, 8.7, 5.0) 16, 17a, 18 15, 16, 18, 19, 26, 27 17a, 27 
18 33.4, CH 1.75, m 17, 19, 26 16, 17, 19, 20, 26  
19 77.4, CH 4.71, dt (10, 2.4) 18, 20 1, 17, 20, 21,26 21, 26 
20a 27.9, CH2 1.52
a
, m 19, 21   
20b  1.47
a
, m 19, 21   
21 22.0, CH2 1.30
b
, m 20  19 
22 36.1, CH2 1.31
b
, m 23  23, 23-OH 
23 70.8, CH 3.28, m 22, 23-OH, 24 21, 22, 25 22, 25, 26 
23-OH  4.25, d (5.2) 23 22, 23, 24 22, 26 
24a 29.7, CH2 1.30
b
, m 23, 25  25 
24b  1.27
b
, m 23, 25  25 
25 10.1, CH3 0.82, t (7.4) 24 23, 24 23, 24 
26 17.5, CH3 0.88, d (6.2) 18 17, 18, 19 
19, 23, 23-
OH 
27 21.5, CH3 0.84, d (6.8) 16 15, 16, 17 16, 17b 
28 17.0, CH3 1.53
a
, s  13, 14, 15 16 
29 17.7, CH3 0.58, d (6.7) 12 11, 12, 13 11, 15 
30 11.1, CH3 0.86, d (5.9) 10 9, 10, 11 9, 11 
a, b
 signals are overlapping. 
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Figure 1. Selected HMBC correlations relevant for the structure elucidation of 1. 
 
 
 
 
 
 
 
Table 2. NMR spectroscopic data of the levantilides in acetone-d6 (500 MHz). 
 levantilide A (1) levantilide B (2) 
  C H C H
1 166.9  166.9  
2 122.0 5.83 121.9 5.83 
3 144.3 7.14 144.4 7.15 
4 131.9 6.36 131.9 6.36 
5 140.1 6.09 140.2 6.11 
6a 40.6 2.69 40.6 2.66 
6b  2.47  2.46 
7 69.3 4.11 69.4 4.10 
8a 33.8 1.73 33.9 1.72 
8b  1.34  1.34 
9 69.3 4.18 69.4 4.17 
10 42.2 1.86 42.3 1.86 
11 77.4 3.17 77.4 3.18 
12 33.2 1.41 33.3 1.41 
13a 41.4 2.00 41.4 1.99 
13b  1.69  1.69 
14 134.1  134.1  
15 134.1 4.86 134.1 4.87 
16 30.7 2.70 30.7 2.69 
17a 41.9 1.47 41.9 1.43 
17b  1.12  1.11 
18 34.7 1.87 34.7 1.87 
19 78.8 4.83 78.6 4.81 
20a 28.9 1.61 28.3 1.57 
20b  1.53  1.50 
21a 23.3 1.42 21.3 1.62 
21b    1.47 
22 37.6 1.42 42.1 2.45 
23 72.7 3.42 210.5  
24a 31.1 1.43 36.0 2.42 
24b  1.37   
25 10.4 0.90 8.0 0.96 
26 18.6 0.91 18.4 0.91 
27 22.0 0.86 21.8 0.87 
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Table 2. Cont. 
28 17.6 1.62 17.6 1.63 
29 18.5 0.70 18.4 0.71 
30 10.8 0.98 11.0 0.98 
The levantilides are macrolides with a 20-membered lactone ring. From a biosynthetic point of 
view macrolides are typical type I PKS products with very well studied biosynthetic pathways. From 
the structures of the levantilides, a very simple assembly of a propionate starter unit, five further 
propionate building blocks and altogether six acetate building blocks can be deduced. 
Cytotoxicity tests of 1 revealed antiproliferative activities against gastric tumor cells GXF 251L 
(IC50 = 40.9 µM), lung tumor cells LXFL 529L (IC50 = 39.4 µM), mammary tumor cells MAXF 
401NL (IC50 = 28.3 µM), melanoma tumor cells MEXF 462NL (IC50 = 48.6 µM), pancreas tumor cells 
PAXF 1657L (IC50 = 20.7 µM) and renal tumor cells RXF 486L (IC50 = 52.4 µM). Antimicrobial 
activity against the bacteria and fungi in the test panel were not observed for compounds 1 and 2. 
Members of the Actinomycetes are well known to produce macrolide antibiotics [10]. 
Micromonospolides, mycinamicins, megalomicin, rosamicin and juvenimicins are e.g., macrolide 
antibiotics produced by members of the genus Micromonospora, but they all differ in the size of the 
macrolide ring from the levantilides [11–15]. The levantilides are 20-membered macrolides without an 
attached sugar and are, for example, related to the cytotoxic macrolides amphidinolide A and  
U [16,17] as well as to iriomoteolide 1a, b and c [18,19]. These compounds are also 20-membered 
marcolides which exhibit cytotoxic activity against several human tumor cell lines [20–22] and are 
produced by the marine symbiontic dinoflagellate Amphidinium sp. Iriomotolide 1a, 1b and 1c show 
remarkable cytotoxicity against B lymphocyte cells DG75 (IC50 = 0.0039 µM, 1.7 µM and 0.0038 µM) 
while amphidinolide A and U possess cytotoxic activities against murein lymphoma cells L1210  
(IC50 = 3.7 µM and 10.7 µM) and against human epideromoid carcinoma cells (IC50 = 10.7 µM and 
35.08 µM).  
According to Skropeta (2008), polyketide metabolites have been reported from all water depths, but 
interestingly only 8% of the marine natural products known so far are produced by organisms obtained 
at depth greater than 1000 m [23]. As a matter of course, this might be due to the fact that the deep sea 
is hardly accessible. In the present study, it was shown by cultivation of strain M71-A77 with habitat 
sea water (38.6‰) that levantilides are also produced under the high salinity conditions occurring in 
situ in the Mediterranean Sea. Though strains of Micromonospora spp. were frequently isolated from 
deep sea habitats [24–26], to the best of our knowledge the levantilides are the first natural products 
described from a Micromonospora sp. strain isolated from the deep sea. 
3. Experimental Section 
3.1. Isolation and identification of strain M71-A77 
Strain M71-A77 has been isolated from a sediment core (1.5–5 cm sediment horizon) from 4400 m 
depth during a research cruise with RV Meteor M71/2 in the Eastern Mediterranean Sea, the so-called 
Levantine Sea [34° 25.48 N, 26° 05.39 E]. One gram of the sediment sample was transferred to a 
sterile petri dish and dried for 2 months at 20 °C prior to incubation for 1 h at 120 °C dry heat. 
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Sediment was then re-suspended in demineralized water and inoculated on agar plates of XJ4-medium 
containing of 1 L of demineralized water 18 g agar, 0.1 g histidine, 1 g raffinose, 0.5 g sodium 
hydrogen phosphate, 1.7 g potassium chloride, 0.05 g magnesium sulfate, 0.01 g iron sulfate, 0.02 g 
calcium carbonate, 0.5 mg thiamine hydrogen chloride, 0.5 mg riboflavine, 0.5 mg niacine, 0.5 mg 
piridoxin, 0.5 mg calcium pantothenate, 0.5 mg inositol, 0.5 mg para aminobenzoic acid and 0.25 mg 
biotin. After 2 months of incubation at 28 °C, strain M71-A77 was isolated by transferring to fresh  
XJ4-medium. The strain was classified by 16S rRNA gene sequence analysis according to Gärtner  
et al. [27]. The 16S rRNA gene sequence was deposited in the EMBL Nucleotide Sequence Database 
and was assigned the accession no. FR714833.  
3.2. Chemical analysis 
General experimental procedures. The optical rotation was measured on a Perkin Elmer model 
241 polarimeter. UV-spectra were obtained on a NanoVue (GE Healthcare). NMR spectra were 
recorded on a Bruker DRX500 spectrometer (500 and 125 MHz for 
1
H and 
13
C NMR, respectively), 
using the signals of the residual solvent protons and the solvent carbons as internal references (δH 2.04 
and δC 28.9 ppm for acetone-d6; δH 2.50 and δC 39.51 ppm for DMSO-d6). High-resolution mass 
spectra were acquired on a benchtop time-of-flight spectrometer (MicrOTOF, Bruker Daltonics) with 
positive electrospray ionization. Analytical reversed phase HPLC-UV/MS experiments were 
performed using a C18 column (Phenomenex Onyx Monolithic C18, 100 × 3.00 mm) applying an H2O 
(A)/MeCN (B) gradient with 0.1% HCOOH added to both solvents (gradient: 0 min 5% B, 4 min 60% 
B, 6 min 100% B; flow 2 mL/min) on a VWR Hitachi Elite LaChrom system coupled to an ESI-ion 
trap detector (Esquire 4000, Bruker Daltonics). Preparative HPLC was carried out using a 
Phenomenex Gemini C18 110A AXIA, 100 × 50.00 mm column.  
Isolation of levantilides A and B. 10 L of liquid starch-peptone medium (1L demineralized water 
10 g starch, 5 g soja peptone, 15 g Tropic Marin® sea salt and 1 g calcium carbonate) were used for 
cultivation of strain M71-A77. After 8 days of incubation (28 °C, 125 rpm), the culture supernatant 
was separated from the cells by centrifugation at 10,000 rpm for 10 min (Beckman J2-MC). Cell 
pellets were suspended in methanol and homogenized three times with an Ultra Turax T25 basic  
(IKA-Werke GmbH & Co., Staufen, Germany) at 17.500 U/min for 1 min. After additional 
centrifugation, the methanol extract was decanted and dried. The culture broth supernatant was 
extracted with ethylacetate (1:1). The dried extracts were dissolved in methanol and analyzed by 
HPLC-UV/MS. Levantilides A and B were detected at 4.2 and 4.5 min with a maximum  
UV-absorption at 260 nm. For structure analysis, 1 and 2 were separated by reversed phase HPLC. For 
that purpose, HCOOH (0.1%) was added to the solvents H2O (A) and MeCN (B) and a gradient from 
10% B over 60% B (reached after 17 min) to 100% B was applied (flow 15 mL/min). Levantilides A 
and B were detected at 16.6 and 17.8 min. Thus, 7 mg of 1 and 3 mg of 2 were obtained. 
Levantilide A (1): colorless, amorphous solid; []20D −72.4 (c 0.145, MeOH); UV (MeOH) λmax 
(log ε) 262 (4.61); for 1D and 2D NMR data see Table 1 and SI; HRESIMS m/z 531.3676 [M + Na]+ 
(C30H52NaO6, 531.3656). 
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Levantilide B (2): colorless, amorphous solid; []20D -97.5 (c 0.04, MeOH); UV (MeOH) λmax 261 
(log ε) (4.48); 1H NMR (acetone-d6, 500 MHz)  7.15 (1H, dd, J = 15.1, 11.0, H-3), 6.36 (1H, dd,  
J = 15.1, 11.0, H-4), 6.11 (1H, ddd, J = 15.1, 9.8, 4.4, H-5), 5.83 (1H, d, J = 15.1, H-2), 4.87 (1H, d,  
J = 8.0, H-15), 4.81 (1H, dt, J = 10.2, 2.5, H-19), 4.17 (1H, dt, J = 11.9, 3.1, H-9), 4.10 (1H, m, H-7), 
3.18 (1H, m, H-11) 2.69 (1H, m, H-16), 2.66 (1H, m, H-6a), 2.46 (1H, m, H-6b), 2.45 (2H, m, H2-22), 
2.42 (2H, q, J = 7.5, H2-24), 1.99 (1H, m, H-13a), 1.87 (1H, m, H-18), 1.86 (1H, m, H-10), 1.72 (1H, 
ddd, J = 15.0, 11.2, 3.3, H-8a), 1.69 (1H, dd, J = 13.1, 10.9, H-13b), 1.63 (3H, s, H3-28), 1.62 (1H, m, 
H-21a), 1.57 (1H, m, H-20a), 1.50 (1H, m, H-20b), 1.47 (1H, m, H-21b), 1.43 (1H, m, H-17a), 1.41 
(1H, m, H-12), 1.34 (1H, ddd, J = 15.0, 5.4, 3.0, H-8b), 1.11 (1H, ddd, J = 14.6, 9.0, 5.1, H-17b), 0.98 
(3H, d, J=7.0, H3-30), 0.96 (3H, t, J = 7.5, H3-25), 0.91 (3H, d, J = 7.5, H3-26), 0.87 (3H, d, J = 7.0, 
H3-27), 0.71 (3H, d, J = 7.0, H3-29); for 
13
C NMR data see Table 2; HRESIMS m/z 529.3509  
[M + Na]
+
 (C30H50NaO6, 529.3500). 
3.3. Production of levantilide A (1) and B (2) at in situ salinity  
Strain M71-A77 was tested for the production of secondary metabolites at habitat salinity (38.6 ‰). 
For that purpose, Tropical Marine® salt and aqua dest. were replaced by Mediterranean Sea water 
obtained from the sampling site. After 8 days of cultivation at 28 °C, the culture broth was extracted 
with ethylacetate and analyzed by analytical HPLC-UV/MS as described above. 
3.4. Antimicrobial tests 
Antimicrobial activity of compound 1 and 2 (100 µM) was tested against the Gram-positive bacteria 
Bacillus subtilis (DSM 347), Staphylococcus lentus (DSM 6672), the Gram-negative bacteria 
Xanthomonas campestris (DSM 2405), Escherichia coli (DSM 498), Erwinia amylovora (DSM 
50901), Pseudomonas fluorescens (NCIMB 10586), Pseudomonas syringae (DSM 50252), Ralstonia 
solanacearum (DSM 9544), the yeast Candida glabrata (DSM 6425) and the fungus Septoria tritici as 
described by Lang et al. in 2007 [28]. The results were compared to a positive (100 µM 
chloramphenicol for bacteria and 100 µM cycloheximide for C. glabrata and S. tritici) and a negative 
(no compound) control on the same plate. 
3.5. Cytotoxic tests 
The in vitro antiproliferative activities of compound 1 against the gastric cancer cell line GXF 
251L, lung cancer cell line LXFL 529L, melanoma cancer cell line MEXF 462NL, mammary cancer 
cell line MAXF 401NL, renal cancer cell line RXF 486L and pancreatic cancer cell line PAXF 1657L 
were determined by Oncotest GmbH (Freiburg, Germany) using a modified propidium iodide 
monolayer assay [29]. Compound 2 was not tested by Oncotest GmbH, for there was not enough left 
of the compound. 
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